IL297687A - Histone deacetylase inhibitors for immune modulation in the tumor microenvironment - Google Patents
Histone deacetylase inhibitors for immune modulation in the tumor microenvironmentInfo
- Publication number
- IL297687A IL297687A IL297687A IL29768722A IL297687A IL 297687 A IL297687 A IL 297687A IL 297687 A IL297687 A IL 297687A IL 29768722 A IL29768722 A IL 29768722A IL 297687 A IL297687 A IL 297687A
- Authority
- IL
- Israel
- Prior art keywords
- gntbm
- compound
- cells
- tumor
- dynamicpdf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063018427P | 2020-04-30 | 2020-04-30 | |
| PCT/CN2021/090718 WO2021219040A1 (en) | 2020-04-30 | 2021-04-28 | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL297687A true IL297687A (en) | 2022-12-01 |
Family
ID=78373345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297687A IL297687A (en) | 2020-04-30 | 2021-04-28 | Histone deacetylase inhibitors for immune modulation in the tumor microenvironment |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11672788B2 (enExample) |
| EP (1) | EP4142733B1 (enExample) |
| JP (1) | JP7748392B2 (enExample) |
| KR (1) | KR20230005939A (enExample) |
| CN (1) | CN116033904A (enExample) |
| AU (1) | AU2021265994B2 (enExample) |
| BR (1) | BR112022022015A2 (enExample) |
| ES (1) | ES3051512T3 (enExample) |
| HR (1) | HRP20251279T1 (enExample) |
| IL (1) | IL297687A (enExample) |
| MX (1) | MX2022013634A (enExample) |
| PL (1) | PL4142733T3 (enExample) |
| TW (1) | TWI849310B (enExample) |
| WO (1) | WO2021219040A1 (enExample) |
| ZA (1) | ZA202212650B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115322171B (zh) * | 2022-08-30 | 2023-03-17 | 深圳微芯生物科技股份有限公司 | 一种trka(g667c)和flt3靶点抑制剂及其与西达本胺的组合物 |
| CN122036601A (zh) * | 2024-11-15 | 2026-05-15 | 深圳微芯生物科技股份有限公司 | 一种苯甲酰胺类衍生物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| EP1641458A2 (en) | 2002-12-27 | 2006-04-05 | Schering Aktiengesellschaft | Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors |
| CA2552279C (en) * | 2003-12-02 | 2014-07-15 | The Ohio State University Research Foundation | Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors |
| CA2702536A1 (en) | 2007-10-10 | 2009-04-16 | Orchid Research Laboratories Limited | Novel histone deacetylase inhibitors |
| CN106916100B (zh) * | 2014-04-04 | 2020-09-15 | 深圳微芯生物科技股份有限公司 | 一种e构型苯甲酰胺类化合物及其药用制剂 |
| CN106916101B (zh) | 2017-02-15 | 2020-05-01 | 聚缘（上海）生物科技有限公司 | Nampt/hdac双靶点抑制剂及其制备方法 |
| TR201900059A2 (tr) * | 2018-01-05 | 2019-07-22 | Gnt Biotech & Medicals Corp | Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem |
-
2021
- 2021-04-28 HR HRP20251279TT patent/HRP20251279T1/hr unknown
- 2021-04-28 MX MX2022013634A patent/MX2022013634A/es unknown
- 2021-04-28 WO PCT/CN2021/090718 patent/WO2021219040A1/en not_active Ceased
- 2021-04-28 JP JP2022565835A patent/JP7748392B2/ja active Active
- 2021-04-28 BR BR112022022015A patent/BR112022022015A2/pt not_active Application Discontinuation
- 2021-04-28 PL PL21796395.8T patent/PL4142733T3/pl unknown
- 2021-04-28 AU AU2021265994A patent/AU2021265994B2/en active Active
- 2021-04-28 ES ES21796395T patent/ES3051512T3/es active Active
- 2021-04-28 KR KR1020227042007A patent/KR20230005939A/ko active Pending
- 2021-04-28 EP EP21796395.8A patent/EP4142733B1/en active Active
- 2021-04-28 IL IL297687A patent/IL297687A/en unknown
- 2021-04-28 TW TW110115446A patent/TWI849310B/zh active
- 2021-04-28 US US17/243,378 patent/US11672788B2/en active Active
- 2021-04-28 CN CN202180031935.4A patent/CN116033904A/zh active Pending
-
2022
- 2022-11-21 ZA ZA2022/12650A patent/ZA202212650B/en unknown
-
2023
- 2023-05-01 US US18/310,387 patent/US12213971B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES3051512T3 (en) | 2025-12-29 |
| JP2023524230A (ja) | 2023-06-09 |
| JP7748392B2 (ja) | 2025-10-02 |
| CN116033904A (zh) | 2023-04-28 |
| US12213971B2 (en) | 2025-02-04 |
| EP4142733C0 (en) | 2025-10-01 |
| EP4142733A4 (en) | 2023-03-08 |
| KR20230005939A (ko) | 2023-01-10 |
| HRP20251279T1 (hr) | 2025-12-05 |
| CA3176748A1 (en) | 2021-11-04 |
| US11672788B2 (en) | 2023-06-13 |
| WO2021219040A1 (en) | 2021-11-04 |
| TW202200557A (zh) | 2022-01-01 |
| US20230263790A1 (en) | 2023-08-24 |
| ZA202212650B (en) | 2024-04-24 |
| US20210379032A1 (en) | 2021-12-09 |
| PL4142733T3 (pl) | 2026-01-19 |
| AU2021265994B2 (en) | 2024-02-29 |
| MX2022013634A (es) | 2022-11-16 |
| TWI849310B (zh) | 2024-07-21 |
| NZ794355A (en) | 2026-02-27 |
| EP4142733A1 (en) | 2023-03-08 |
| BR112022022015A2 (pt) | 2022-12-13 |
| AU2021265994A1 (en) | 2022-12-15 |
| EP4142733B1 (en) | 2025-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11826363B2 (en) | Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient | |
| JP7104633B2 (ja) | Ｎｌｒｐ３修飾因子 | |
| JP6342393B2 (ja) | 置換型ピラゾロン化合物及び使用方法 | |
| IL272165A (en) | Opioid receptor ligands and methods of using and making same | |
| IL307361B2 (en) | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer | |
| JP2021054856A (ja) | トリアジン化合物及びその医薬用途 | |
| CN102459187A (zh) | Janus激酶抑制化合物和方法 | |
| CN102675282B (zh) | 取代的喹啉化合物及其使用方法和用途 | |
| WO2019014402A1 (en) | MODULATORS OF NLRP3 | |
| CN103539780A (zh) | 取代的吡唑酮化合物及其使用方法和用途 | |
| US12213971B2 (en) | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment | |
| AU2010333082A1 (en) | 3-(indolyl)-or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarzinoma | |
| WO2020150115A1 (en) | Nlrp3 modulators | |
| JP2025516359A (ja) | テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 | |
| CA3176748C (en) | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment | |
| RU2854218C1 (ru) | Ингибиторы гистондеацетилазы для иммуномодуляции в микросреде опухоли | |
| HK40092030A (en) | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment | |
| WO2008020606A1 (en) | Antiangiogenic agent | |
| EP4552695A2 (en) | Tyrosine kinases inhibitors and uses thereof | |
| BR102024021500A2 (pt) | Composto, composição farmacêutica e métodos para suprimir a angiogênese, para suprimir a metástase, para suprimir a oncogênese, para modular as atividades de regulação imunológica, para tratar ou prevenir uma doença e para tratar tumores ou cânceres |